Is lexapro activating or sedating
In January 2003, fluoxetine was approved by the FDA for the treatment of depression and OCD in children and adolescents who are seven to 17 years of age.6 Because fluoxetine has a half-life of two to four days and its active ingredient, norfluoxetine, has a half-life of seven to nine days, it is reasonable to wait four weeks between dose titrations.
Fluoxetine is now available in a special form taken once-weekly for continuation therapy of depression.
Prozac Weekly is a capsule with pellets containing 90 mg of fluoxetine hydrochloride.
The enteric coating prevents dissolution of the pellets until they have passed into the portion of the gastrointestinal tract where the p H exceeds 5.5.6 In a study8 of 500 patients with depression, the percentage of patients relapsing during continuation treatment with a 90-mg weekly dose was not significantly different from those taking a 20-mg daily dose. Weekly dosing is recommended to begin seven days after the last daily dose of 20 mg .
The most common side effects of sertraline are nausea, dry mouth, fatigue, and decreased libido.
Treatment with sertraline should be started at 50 mg, either daily throughout the month or daily during the luteal phase of the menstrual cycle.
Thus, non-continuous use of fluoxetine for this indication may be an effective option. Stamford, Conn.: Appleton & Lange, 1999;1154–5Any drug that increases serotonin concentrations, including: MAOIs, tramadol (Ultram), sibutramine (Meridia), meperidine (Demerol), sumatriptan (Imitrex), lithium, St. The initial dose in children (six to 12 years of age) with OCD is 25 mg; patients who are at least 13 years of age may take adult doses.
New indications for selective serotonin reuptake inhibitors include post-traumatic stress disorder, premenstrual dysphoric disorder, and generalized anxiety disorder.The newest indication for sertraline is the treatment of PMDD.Sertraline has been shown to improve quality-of-life scores and psychologic and behavior symptoms in patients with PMDD.1516 [Reference 15—Evidence level A, RCT] Its effectiveness has been demonstrated with both continuous dosing throughout the month and luteal-phase dosing.Fluoxetine (under the trade name Sarafem) is now indicated for the treatment of premenstrual dysphoric disorder (PMDD), also known as late luteal dysphoric disorder or premenstrual syndrome.Improvement in symptoms of tension, irritability, and dysphoria has been demonstrated.9 [Evidence level A, randomized controlled trial (RCT)] Side effects were comparable with those reported in studies of fluoxetine used for other indications.